Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors
Blocking interaction of the immune checkpoint receptor PD-1 with its ligand PD-L1 is associated with good clinical outcomes in a broad variety of malignancies. High levels of PD-L1 promote tumor growth by restraining CD8+ T-cell responses against tumors. Limiting PD-L1 expression and function is the...
Main Authors: | Eva M. Palsson-McDermott, Lydia Dyck, Zbigniew Zasłona, Deepthi Menon, Anne F. McGettrick, Kingston H. G. Mills, Luke A. O’Neill |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01300/full |
Similar Items
-
Involvement of Lactate and Pyruvate in the Anti-Inflammatory Effects Exerted by Voluntary Activation of the Sympathetic Nervous System
by: Jelle Zwaag, et al.
Published: (2020-04-01) -
Posttranslational Modifications of Pyruvate Kinase M2: Tweaks that Benefit Cancer
by: Gopinath Prakasam, et al.
Published: (2018-02-01) -
Maturation of pig oocytes in vitro in a medium with pyruvate
by: H. Gonzales-Figueroa, et al.
Published: (2005-06-01) -
Conversion of phosphoenolpyruvate to pyruvate in Thermoanaerobacterium saccharolyticum
by: Jingxuan Cui, et al.
Published: (2020-06-01) -
Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform
by: Xianling Ning, et al.
Published: (2018-01-01)